Overview

Gender

male

Investor Type

Angel

Tony joined Ablynx as Chief Scientific Officer in October 2013. In this role, he leads the company’s discovery organization.

Tony has more than 15 years of biotech R&D experience and expertise in building out pipelines and expanding platform technologies. Prior to joining Ablynx, Tony was CSO at Moderna Therapeutics where he led the science, helping to grow the company from a start-up to an established biotech with over 70 people and a $240M upfront pre-clinical deal with Astra Zeneca. Previously, Tony was CSO at Tolerx Incand prior to that he served on the management team of Alnylam Pharmaceuticals as Vice President, Research, Immunology, Metabolic, and Viral Disease from 2003-2010. He also served as a Principal Scientist at Biogen, Inc. (now Biogen Idec Inc.) from 1998-2003 where he worked on several immunology/inflammation-based programs and led research teams working to develop antibody-based therapeutics.

Tony has been Principal Investigator on numerous grant awards totaling over $80M, and was named by Pharmaceutical Executive magazine as an “Emerging Pharma Leader” in 2009. Tony has over 60 scientific publications and is an inventor on over 30 issued U.S. patents. He earned his Ph.D. in Immunology from Harvard University, and was an Arthritis & Rheumatism Council (ARC) Research Fellow at the Laboratory of Molecular Biology in Cambridge, England.